Vor Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
VOR$19.56-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year EndedDecember 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2023 | 2022 |
| Operating expenses: | ||
| Research and development | $94,315 | $64,550 |
| General and administrative | 31,721 | 28,868 |
| Total operating expenses | $126,036 | $93,418 |
| Loss from operations | $(126,036) | $(93,418) |
| Other income: | ||
| Interest income | 8,173 | 1,324 |
| Total other income | 8,173 | 1,324 |
| Net loss | $(117,863) | $(92,094) |
| Net loss per share attributable to common stockholders, basic and diluted | $(1.75) | $(2.33) |
| Weighted-average common shares outstanding, basic and diluted | 67,191,973 | 39,551,420 |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on available for sale investments | 693 | (770) |
| Total other comprehensive income (loss) | 693 | (770) |
| Comprehensive loss | $(117,170) | $(92,864) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.